Professional Documents
Culture Documents
PII: S0960-894X(18)30418-9
DOI: https://doi.org/10.1016/j.bmcl.2018.05.019
Reference: BMCL 25836
Please cite this article as: Yang, S., Lu, D., Ouyang, P., Design, synthesis and evaluation of novel N-
phenylbutanamide derivatives as KCNQ openers for the treatment of epilepsy, Bioorganic & Medicinal Chemistry
Letters (2018), doi: https://doi.org/10.1016/j.bmcl.2018.05.019
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers
we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and
review of the resulting proof before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Design, synthesis and evaluation of novel N-phenylbutanamide
Abstract
KCNQ (Kv7) has emerged as a validated target for the development of novel
anti-epileptic drugs. In this paper, a series of novel N-phenylbutanamide derivatives
were designed, synthesized and evaluated as KCNQ openers for the treatment of
epilepsy. These compounds were evaluated for their KCNQ opening activity in vitro
and in vivo. Several compounds were found to be potent KCNQ openers. Compound
1 with favorable in-vitro activity was submitted to evaluation in vivo. Results showed
that compound 1 owned significant anti-convulsant activity with no adverse effects. It
was also found to posses favorable pharmacokinetic profiles in rat. This research may
provide novel potent compounds for the discovery of KCNQ openers in treating
epilepsy.
In our previous work for the discovery of novel AEDs, we designed a series of
piperidine containing compounds as Kv7 openers based on the structure of RTG and
PF-05020182 using hybridization drug design strategy [14]. As a continuous
optimization, herein we described the design, synthesis and evaluation of a novel
series of N-phenylbutanamide derivatives as Kv7 openers for treatment of epilepsy. In
this series, different fused heterocycles were designed to fix at the N-phenyl tail
(Figure 2). Target compounds were examined for the Kv7 opening activity in vitro.
The potent compounds were further evaluated for anti-convulsant activity and safety
profile in vivo. Meanwhile, the in-vivo pharmacokinetic evaluation was also
performed.
1 7
2 8
3 9
4 10
5 11
6 12
Rb+ flow test is an efficient and reliable method in the high throughput screening
of potasium channel regulators [15, 16]. The target compounds were initially evaluated
by Rb+ flow test, and the results are summarized in Table 2. Selected compounds were
further evaluated by Thallium test and patch-clamp test to verify their activities on
KCNQ2.
It was found that most of the tested compounds showed stronger activity than
RTG in Rb+ flow test. Compound 1 with a thieno[3,2-c]piperidine fragment gave an
EC50 value of 0.02 μM, about 17 fold enhancement compared with that of RTG. When
electron-withdrawing substituents trifluoromethyl or cyano group were introduced to
the ortho-position of sulfur atom, an significant decrease in activity was observed for
compounds 2 and 3 compared with compound 1. Although less potent than compound
1, compounds 2 and 3 were still superior to RTG. A methyl group with electron
donating effect was introduced to the meta-position of sulfur atom to obtain
compound 4 with an EC50 value of 0.3 μM which was equivalent to RTG. But in
comparation with compound 1, compound 4 still afforded a reduced activity.
We then changed the position of sulfur to lead to compounds 5-7, which
containing a thieno[2,3-c]piperidine fragment. Compound 5 showed an equivalent
activity to compound 1. For compound 6, the introduction of electron-withdrawing
fluorine to the ortho-position of sulfur was detrimental to the activity. Compared with
RTG or compound 5, a nearly 10 fold or 150 fold decrease in activity was observed
for compound 6, respectively. While the introduction of electron donating methyl
group in compound 7 slightly influenced the activity compared to compound 5.
Compound 8 was designed as bioisostere of compound 1. As shown in Table 2, a
slightly decrease in activity was observed for compound 8 with an EC50 of 0.034 μM
compared with compound 1 (0.02 μM). To explore the structure activity relationship
of this fragment, the 1-benzazepine which containing a seven membered ring was
introduced in replacement of the piperidine fragment to obtain compounds 9-12.
These compounds were substituted by electron withdrawing halogen or electron
donating methyl group on 7-position of benzazepine ring. As shown in Table 2,
except for the bromo-substituted compound 11, other compounds all exhibited
stronger activity than RTG but weaker than compound 1. The fluoro and chloro
substituted compounds 9 and 10 were apparently superior to bromo-substituted
compound 11. In particular, as observed for compound 12, the replacement of halogen
with an electron donating methyl group significantly elevated the activity.
Table 2. Rb+ flow test results of target compounds.
1 0.02 8 0.034
2 0.12 9 0.25
3 0.29 10 0.14
4 0.30 11 1.08
5 0.02 12 0.04
6 2.93
Compounds 1, 5 and 8 with best activity in Rb+ flow test were further evaluated
by Thallium test to confirm the KCNQ2 opening activity [17]. As shown in Table 3,
compound 1 was the most potent one with a two fold activation ratio of RTG. The
isomer compound 5 also presented a 1.5 fold stronger activity than RTG. But it was
unexpected that compound 8 showed very weak activity in this test. These three
compounds were also evaluated by patch-clamp test to verify their channel opening
activity [17]. As shown in Table 4, compounds 1 and 8 were comparable to RTG. And
compound 1 was able to obviously elevate the –⊿V1/2.
1 84.24 8 4.87
Table 4. Patch-clamp test results of target compounds.
RTG 25 mg/kg 20 3 15 20 0 0
1 5 mg/kg 10 2 20 10 0 0
1 3 mg/kg 10 2 20 10 0 0
1 1 mg/kg 10 9 90 10 0 0
1 0.3 mg/kg 10 7 70 10 0 0
Mice No. 1 2 3 1 2 3 1 2 3
Brain (ng/g) 1.28 0.97 1.55 15.79 16.35 24.89 145.82 112.99 160.72
Plasma (ng/mL) 8.65 5.91 8.99 116.70 129.68 163.90 877.79 625.84 807.94
Mice No. 1a 2 3 1 2 3 1 2 3
Brain (ng/g) 5.41 4.52 22.55 26.37 41.19 25.93 21.46 27.70
Plasma (ng/mL) 61.74 44.09 173.77 227.55 329.07 226.10 172.31 203.43
Rat
Abbreviations
KCNQ (Kv7), voltage gated potassium channel 7; RTG, Retigabine; FDA, Food and
Drug Administration; AEDs, anti-epileptic drugs; PK, pharmacokinetic; MES,
maximal electroshock; EP, epilepsy.
Supplementary Information.